Screener
D&A at other companies
Segments
By segment
Other financials
Where this comes from
Reported directly by Fulgent Genetics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:DepreciationDepletionAndAmortization.
The source filing: Fulgent Genetics, Inc.’s 10-Q, filed May 1, 2026.
- Filed
- May 1, 2026, 7:08 AM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001193125-26-199065
| Line item | Three Months Ended March 31, 2026 | Three Months Ended March 31, 2025 |
|---|---|---|
| Net loss from consolidated operations | $(25,274) | $(11,899) |
| Adjustments to reconcile net loss to net cash provided by (used in) operating activities: | ||
| Equity-based compensation | 9,890 | 10,550 |
| Depreciation and amortization | 6,000 | 5,919 |
| Adjustment for credit losses | 1,189 | 2,075 |
| Noncash lease expense | 352 | 350 |
| Gain on disposal of fixed asset | (9) | (2) |
| Amortization of premium of marketable securities | (890) | (1,658) |
Item 1. Financial Statements.
FAQ
- What is Fulgent Genetics, Inc.'s D&A?
- Fulgent Genetics, Inc. (FLGT) reported D&A of $6M in Q1 2026.
- How has Fulgent Genetics, Inc.'s D&A changed year-over-year?
- Fulgent Genetics, Inc.'s D&A increased by 1.4% year-over-year, from $5.92M to $6M.
- What is the long-term trend for Fulgent Genetics, Inc.'s D&A?
- Over 4 years (2021 to 2025), Fulgent Genetics, Inc.'s D&A has grown at a 21.7% compound annual growth rate (CAGR), from $11M to $24.12M.
- What does D&A mean?
- Total non-cash depreciation of tangible assets and amortization of intangible assets — the largest add-back to net income in the operating cash flow reconciliation.
Ask your AI about Fulgent Genetics, Inc.'s d&a.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude